The purpose of this focused update is to update the “2013 ACCF/AHA Guideline for the
Management of Heart Failure” 9 (2013 HF guideline) in areas in which new evidence has …

The natriuretic peptides are important tools to establish diagnosis and prognosis in heart
failure (HF). With application of therapies for HF, changes in both B-type natriuretic peptide …

Background: Soluble suppression of tumorigenesis-2 (sST2) is a biomarker related to
inflammation and fibrosis. Objectives: This study assessed the independent prognostic value …

Januzzi and Troughton Usefulness of NP-Guided Therapy 501 clinician judgment.
Furthermore, to achieve goals of therapy as outlined in guidelines, frequent office visits for …

This study sought to evaluate the potential of circulating long non‐coding RNA s (lnc RNA s)
as biomarkers for heart failure (HF). We measured the circulating levels of 13 individual lnc …

Background Cardiac rehabilitation (CR) improves the symptoms, exercise capacity and
quality of life of chronic heart failure (CHF) patients. Its effects on new plasma biomarkers of …

In contrast to public perception, the morbidity and mortality and the resultant healthcare
costs associated with chronic heart failure (HF) are increasing and arguably reaching …

Background Obese patients have lower NT‐proBNP (N‐terminal pro‐B‐type natriuretic
peptide) levels. The prognostic implications of achieving NT‐proBNP levels≤ 1000 pg/mL in …

Heart failure (HF) is a complex disease process that is challenging to diagnose and
manage. For more than 15 years, biomarkers have been used to diagnose and the guide the …

Background The B-type natriuretic peptides are now available on many automated clinical
analysers. Clinical practice guidelines for heart failure include recommendations for where …